The interleukin-8 luciferase (IL-8 Luc) assay is an in vitro method for detecting IL-8 promotor activity, for which an increase is directly linked to Key Event 3 (KE3) in the OECD’s Adverse Outcome Pathway (AOP) for skin sensitisation. The OECD has recently validated the assay, concluding that it is well defined, with a clear protocol and criteria for data evaluation, and with some advantages (over existing KE3 methods) in terms of technical performance and time requirements. As such, it was concluded that the IL-8 Luc assay should be adopted as part of the Integrated Testing Strategy for skin sensitisation.

Organisation for Economic Co-operation and Development (2017). Validation report for the international validation study on the IL-8 Luc assay as a test evaluating the skin sensitizing potential of chemicals conducted by the IL-8 Luc Assay. Series on Testing & Assessment No. 267. ENV/JM/MONO(2017)19. 20 July 2017. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2017)19&doclanguage=en

Report of the Peer Review Panel for the IL-8 Luciferase (IL-8 Luc) Assay for in vitro skin sensitisation. Series on Testing & Assessment No 268. ENV/JM/MONO(2017)20. 20 July 2017. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2017)20&doclanguage=en

 

The above items were taken from the October 2017 issue of Toxicology and Regulatory News which is sent automatically to members of bibra.

News Home Guest Write For Us? Contact Us